• Please join IMMUNICUM at our
    April 2018 Investor Events

    Stockholm (April 11) and Gothenburg (April 18)

    We kindly request you to RSVP with your full name and at which location you would attend. The RSVP will confirm your spot at the requested location. Registration for each event will close once capacity is reached.

    Confirm by RSVP
  • Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

    Learn more

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

We are on a journey towards the world’s first patient unique, off-the-shelf cancer treatment. Get to know the technology that will take us there.

Learn more